An interventional study of Endocuff colonoscopy and control in Serrated Lesion, Adenoma and Colorectal Cancer, sponsored by Hospital Beatriz Ângelo. Completed at 1 site in Portugal. Open to participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-16.
Sponsored by Hospital Beatriz Ângelo · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Colorectal cancer (CRC) is a leading cause of morbidity and mortality worldwide, especially in Western countries. CRC is currently considered a preventable disease and screening has been endorsed by several societies, since it has been shown that screening and surveillance are effective in reducing both CRC incidence and mortality. However, recently, concern has risen regarding colonoscopy effectiveness, especially in the right colon. The most accepted explanation for this effectiveness variability is attributed to sessile serrated lesions (SSL), which are more frequent in the proximal colon, more difficult to detect because of their flat morphology and associated with interval CRC, which is the occurrence of CRC after screening colonoscopy and before the next scheduled procedure. Several techniques are emerging to increase the sensitivity of colonoscopy for pre-cancerous lesions, especially adenomas. Recently an endoscopic cap, the Endocuff, was developed to improve adenoma detection. Several studies demonstrated improved adenoma detection with Endocuff-assisted colonoscopy when compared with conventional colonoscopy. Still, the available data for its' role in detecting SSL is very limited. The aim of this randomized controlled trial is to evaluate the effectiveness of Endocuff-assisted colonoscopy in detection of colorectal SSL.
183 studies on the registry are indexed under Adenoma; 28 are open to participants now.
This study's enrollment of 257 is below the median of 372 across 128 interventional studies indexed under Adenoma.
Browse Adenoma studies →Hospital Beatriz Ângelo is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Colonoscopy performed with Endocuff
Device: Endocuff colonoscopy
Colonoscopy performed without any device
Device: control
Colonoscopy performed with Endocuff for mucosal inspection and interventions (eg. polypectomy).
colonoscopy without endocuff
Average number of serrated lesions ≥ 10 mm detected per colonoscopy
Average number of serrated lesions ≥ 10 mm detected per colonoscopy
Time frame: immediate
Serrated lesions detection rate
Number of patients with at least one serrated lesion/total number of participants
Time frame: immediate
Average number of serrated lesions < 10 mm detected per colonoscopy
Average number of serrated lesions \< 10 mm detected per colonoscopy
Time frame: immediate
Average number of adenomas detected per colonoscopy
Average number of adenomas detected per colonoscopy
Time frame: immediate
Adenoma detection rate
Number of patients with at least one adenoma/total number of participants
Time frame: immediate
Adenocarcinoma detection rate
Number of patients with at least one adenocarcinoma/total number of participants
Time frame: immediate
Cecal intubation rate
Proportion of colonoscopies with cecal intubation x100
Time frame: immediate
Cecal incubation time
time from the rectum to cecum in minutes
Time frame: immediate
Withdrawal time
time from the cecum to the rectum in minutes
Time frame: immediate
Incidence of procedure related adverse events
Number of adverse events
Time frame: immediate
Ran from Jun 2018 to primary completion in Mar 2019, 9 months.
Of 44 non-industry interventional studies with no phase under Adenoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's 9 months is below that.
Counting every sponsor, half of 50 studies reached it within 28 months; a quarter within 17 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Beatriz Ângelo